Wolfe Research lowers Paychex stock price target to $130 on mixed results

Paychex (PAYX) shares declined 1.4% following its fiscal Q1 2026 results, despite reporting adjusted EPS of $1.22 (beating forecasts) and a 17% revenue increase to $1.54 billion (meeting expectations). Wolfe Research subsequently lowered its price target to $130 from $140, maintaining an "Underperform" rating due to "confusion on organic MS vs. Paycor trends" and concerns about near-term growth. Similarly, BMO Capital reduced its target to $140, citing uncertainties, contributing to a cautious analyst outlook with five firms recently revising earnings expectations downward for the upcoming period.

Analysis

Paychex (PAYX) presents a conflicting picture for investors, as its shares declined 1.4% despite the company reporting a first-quarter fiscal 2026 adjusted EPS of $1.22, which surpassed the $1.20 forecast, and a 17% revenue increase to $1.54 billion, which met expectations. The negative market reaction, which underperformed the S&P 500, was primarily driven by cautious analyst revisions and concerns about the quality of the results. Wolfe Research lowered its price target to $130 from $140 and reiterated an "Underperform" rating, citing "confusion on organic MS vs. Paycor trends" that suggests a lack of clarity in business segment performance. While Wolfe noted "healthy underlying fundamentals" in the Professional Employer Organization (PEO) segment, its revenue was softer than anticipated. This sentiment was echoed by BMO Capital, which also cut its price target to $140, pointing to business uncertainties and a guidance that assumes improvement in the latter half of the fiscal year. The broader analyst consensus appears to be turning cautious, evidenced by five recent downward revisions to earnings expectations, signaling that the company's elevated P/E ratio of 28.82 faces pressure from perceived weakness in near-term growth prospects.

Key Decisions for Investors

• Investors should look past the headline EPS beat and focus on the underlying segment weakness and analyst concerns, which drove the negative stock reaction.
• Given that current guidance relies on an unconfirmed second-half fiscal 2026 improvement, it is prudent to monitor for concrete signs of this acceleration before considering new or increased positions.
• The stock's P/E ratio of 28.82 implies high growth expectations, which may be difficult to justify amid downward earnings revisions and analyst uncertainty, suggesting a potential for valuation contraction if growth falters.